Biotech News
Lutris Pharma Secures $30 Million to Advance Development of LUT014
Lutris Pharma, a clinical-stage biopharmaceutical company, has raised $30 million in a financing round to advance the development of LUT014, an innovative topically applied gel designed to reduce the acneiform rashes caused by EGFRi therapies, a common side effect of
29 January 2025
Stay ahead of trends and best practices
